[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Damora Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100658363","phase-1-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-mutant-calreticulin-targeted-antibodies-in-calr-mutant-myeloproliferative-neoplasms-100658363",false,"NCT07849231","A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms","A Phase 1\u002F1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms","CLARITY-101","Inclusion Criteria:\n\n* Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol.\n* Diagnosis\u002Fconfirmation of ET or MF as defined in the protocol.\n* Documented CALR exon-9 mutation.\n* Willingness to undergo bone marrow biopsy and aspiration per the Schedule of Assessments.\n\nExclusion Criteria:\n\n* Presence of any malignancy unless participant has been disease free for at least 2 years.\n* History of major bleeding or thrombosis within the last 3 months prior to study enrollment.\n* Prior hematopoietic stem cell transplantation or donor leukocyte infusion, or such transplantation or infusion is planned.\n* Participants with laboratory values exceeding protocol defined thresholds.\n* History of clinically significant or uncontrolled cardiac disease.\n* Active HBV, HCV or HIV.\n* Known hypersensitivity to DMR-001 or ruxolitinib or any of their components.\n\nOther protocol defined Inclusion\u002FExclusion Criteria may apply.","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a multi-center, open-label, Phase 1\u002F1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.",[27],"Myeloproliferative Neoplasms (MPNs)",[29,30,31,32],"Myeloproliferative Neoplasms","Myelofibrosis","Essential Thrombocythemia","CALR mutation","RECRUITING","2026-10-02",{"date":36,"type":37},"2026-10-07","ACTUAL",{"date":39,"type":21},"2026-09",{"date":41,"type":21},"2030-06",{"name":43,"class":44},"Damora Therapeutics","INDUSTRY",4,""]